期刊文献+

脾胃培源方联合化疗治疗脾胃虚弱型进展期胃癌疗效观察 被引量:7

Clinical observation of Piwei Peiyuan Decoction combined with c hemotherapy in the treatment of advanced gastric cancer of Piwei Xuruo type
下载PDF
导出
摘要 目的:观察脾胃培源方联合化疗治疗脾胃虚弱型进展期胃癌患者的临床疗效。方法:选取30例脾胃虚弱型进展期胃癌患者,随机分为治疗组和对照组,每组各15例。对照组予以XELOX方案化疗,治疗组在对照组的基础上加用脾胃培源方口服治疗,观察两组患者治疗前后实体瘤变化、免疫功能指标及不良反应发生率。结果:两组患者治疗的有效率及病灶稳定率相比,差异无统计学意义(P>0.05);对照组患者治疗前后血清中CD3^+、CD4^+、CD8^+细胞水平及CD4^+/CD8^+值相比,差异无统计学意义(P>0.05);治疗组患者治疗前后血清中CD3+、CD4^+、CD8^+细胞水平及CD4^+/CD8^+值相比,差异有统计学意义(P<0.05),且治疗效果优于对照组(P<0.05);治疗组相对于对照组而言,不良反应的发生率较低(P<0.05)。结论:脾胃培源方联合化疗可改善脾胃虚弱型进展期胃癌患者的免疫功能,减少化疗后不良反应的发生。 Objective:To observe the clinical effect of Piwei Peiyuan Decoction combined with chemotherapy in the treatment of Piwei Xuruo type of advanced gastric cancer.Methods:In this study,30 patients with advanced gastric cancer of Piwei Xuruo type were randomly divided into treatment group and control group,15 people in each group.The control group was treated with XELOX regimen chemotherapy,and the treatment group was treated with Piwei Peiyuan Decoction on the basis of the control group.The changes of solid tumor,immunological indexes and the incidence of adverse reactions were observed before and after treatment.Results:There was no significant difference between the two groups(P>0.05)in the effective rate and the stability rate of the focus.The levels of CD3^+,CD4^+,CD8+cells and CD4^+/CD8^+ values in serum of patients in the control group before and after treatment showed no significant difference(P>0.05).In contrast,there was significant difference in the levels of CD3^+,CD4^+,CD8^+ cells and CD4^+/CD8^+ values before and after treatment in the treatment group(P<0.05),and the treatment effect was better than that in the control group(P<0.05).Compared with the control group,the incidence of adverse reactions in the treatment group was lower(P<0.05).Conclusion:Piwei Peiyuan Decoction combined with chemotherapy can improve the immune function of the patients with advanced gastric cancer of Piwei Xuruo type,and reduce the occurrence of adverse reactions after chemotherapy.
作者 李晓伟 马芳琪 魏思媛 周先阳 李学军 LI Xiaowei;MA Fangqi;WEI Siyuan;ZHOU Xianyang;LI Xuejun(The Graduate School,Anhui University of Traditional Chinese Medicine,Anhui Hefei 230031,China;The Second Affiliated Hospital of Anhui University of Traditional Chinese Medicine,Anhui Hefei 230061,China)
出处 《中医药临床杂志》 2020年第4期752-755,共4页 Clinical Journal of Traditional Chinese Medicine
关键词 脾胃培源方 XELOX 进展期胃癌 免疫 Piwei Peiyuan Decoction XELOX advanced gastric cancer immunity
  • 相关文献

参考文献10

二级参考文献116

  • 1Atsushi Tashiro,Masatoshi Sano,Koichi Kinameri,Kazutaka Fujita,Yutaka Takeuchi.Comparing mass screening techniques for gastric cancer in Japan[J].World Journal of Gastroenterology,2006,12(30):4873-4874. 被引量:24
  • 2中国慢性胃炎共识意见(上)(2006,上海)[J].中华消化杂志,2007,27(1):45-49. 被引量:235
  • 3杨华,史国军.胃癌术后中西医结合治疗临床观察30例[J].中医药管理杂志,2007,15(6):454-456. 被引量:17
  • 4Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002 [J]. CA Cancer J Clin, 2005, 55(2) : 74-108.
  • 5Molnarovt: A. Advanced esophageal carcinoma recanalization [ J ]. Klin Onkol, 2008, 21(5): 309-312.
  • 6Siewert JR. Gastric cancer: the dispute between East and West [J]. Gastric Cancer, 2005, 8(2): 59-61.
  • 7Isozaki H, Tanaka N, Okajima K. General and specific prognostic fac- tors of early gastric carcinoma treated with curative surgery [ J ]. Hepa- togastroenterology, 1999, 46 ( 27 ) : 1800-1808.
  • 8Kikuchi S, Sato M, Katada N, et al. Surgical outcome of node-positive early gastric cancer with particular reference to nodal status [ Jl. Anti- cancer Res, 2000, 20(5C) : 3695-3700.
  • 9Zhang Z, Wan J, Zhu C, et al. Direct gastroscopy for detecting gastric cancer in the elderly [J]. ChinMedJ (Engl), 2002, 115(1): 117- 118.
  • 10Kim BS, Cho SW, Min SK, et al. Differences in prognostic factors be- tween early and advanced gastric cancer [ J]. Hepatogastroenterology, 2011, 58(107-108) : 1032-1040.

共引文献1548

同被引文献163

引证文献7

二级引证文献40

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部